Edition:
United States

Kindred Biosciences Inc (KIN.OQ)

KIN.OQ on NASDAQ Stock Exchange Capital Market

12.85USD
12:19pm EST
Change (% chg)

$0.21 (+1.66%)
Prev Close
$12.64
Open
$12.74
Day's High
$12.86
Day's Low
$12.53
Volume
4,497
Avg. Vol
42,165
52-wk High
$15.75
52-wk Low
$7.30

Latest Key Developments (Source: Significant Developments)

Kindred Biosciences Announces Q3 Loss Per Share $0.39
Wednesday, 7 Nov 2018 04:01pm EST 

Nov 7 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.39.Q3 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.  Full Article

Kindred Biosciences Announces Positive Results From Pilot Effectiveness Study
Tuesday, 30 Oct 2018 04:01pm EDT 

Oct 30 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM PILOT EFFECTIVENESS STUDY OF ITS FULLY CANINIZED IL-31 ANTIBODY FOR THE TREATMENT OF ATOPIC DERMATITIS IN DOGS AND ISSUANCE OF U.S. PATENT.KINDRED BIOSCIENCES INC - STATISTICALLY SIGNIFICANT REDUCTION IN PRURITUS VERSUS PLACEBO WAS ACHIEVED ACROSS ALL DOSE GROUPS.KINDRED BIOSCIENCES INC - U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED A PATENT (PATENT NO. 10,093,731) FOR KINDREDBIO'S ANTI-IL31 ANTIBODY.KINDRED BIOSCIENCES INC - BASED ON A PRELIMINARY REVIEW OF SAFETY DATA, IL-31 DRUG APPEARS TO BE WELL TOLERATED.  Full Article

Kindred Biosciences Announces Pricing Of Public Offering
Wednesday, 20 Jun 2018 09:10am EDT 

June 20 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING.SAYS PUBLIC OFFERING OF 4.63 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.SAYS PUBLIC OFFERING OF 4.63 MILLION COMMON SHARES PRICED AT $9.50PER SHARE.  Full Article

Kindred Biosciences Q4 Loss Per Share $0.35
Thursday, 1 Mar 2018 04:01pm EST 

March 1 (Reuters) - Kindred Biosciences Inc ::KINDRED BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.35.  Full Article

KindredBio Announces Submission Of European Medicines Agency Filing For Mirataz
Thursday, 21 Dec 2017 08:02am EST 

Dec 21 (Reuters) - Kindred Biosciences Inc ::KINDREDBIO ANNOUNCES SUBMISSION OF EUROPEAN MEDICINES AGENCY FILING FOR MIRATAZ™.KINDRED BIOSCIENCES INC - EMA HAS ACCEPTED SUBMISSION FOR REVIEW, WITH OFFICIAL ACCEPTANCE DATE OF DECEMBER 21, 2017.KINDRED BIOSCIENCES INC - EXECUTED NATIONAL DISTRIBUTION DEALS WITH MWI VETERINARY SUPPLY CO. & DIRECT VET MARKETING, INC. D/B/A VETS FIRST CHOICE.  Full Article

KindredBio Announces Positive Results From Pivotal Study Of Zimeta Oral
Monday, 4 Dec 2017 08:02am EST 

Dec 4 (Reuters) - Kindred Biosciences Inc ::KINDREDBIO ANNOUNCES POSITIVE RESULTS FROM PIVOTAL STUDY OF ZIMETA ORAL FOR FEVER IN HORSES.KINDRED BIOSCIENCES INC - ‍BASED ON PRELIMINARY REVIEW OF SAFETY DATA, DRUG ZIMETA APPEARS TO BE WELL TOLERATED ​.KINDRED BIOSCIENCES INC - CO ANTICIPATES SUBMITTING EFFECTIVENESS TECHNICAL SECTION OF NEW ANIMAL DRUG APPLICATION IN EARLY 2018​.  Full Article

Kindred Biosciences posts Q3 loss of $0.29 per share
Tuesday, 7 Nov 2017 04:01pm EST 

Nov 7 (Reuters) - Kindred Biosciences Inc :Kindred biosciences announces third quarter 2017 financial results.Q3 loss per share $0.29.Q3 earnings per share view $-0.33 -- Thomson Reuters I/B/E/S.  Full Article

Kindred Biosciences Q2 loss per share $0.29
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Kindred Biosciences Inc :Kindred Biosciences announces second quarter 2017 financial results.Q2 loss per share $0.29.Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Kindred Biosciences - ‍for 2017 , reiterates its previous guidance for operating expenses to be in range of $30 million to $32 million, excluding items​.  Full Article

Kindred Biosciences says board appointed Wendy Wee as CFO - SEC Filing
Friday, 28 Jul 2017 05:19pm EDT 

July 28 (Reuters) - Kindred Biosciences Inc :Kindred Biosciences Inc - On July 24, 2017, board of directors of co appointed Wendy Wee as CFO of company, effective July 28, 2017 - SEC Filing.Kindred Biosciences Inc - As of July 28, 2017, date of Wee's appointment as CFO, Richard Chin no longer serves as interim chief financial officer.  Full Article

KindredBio announces pricing of public offering
Wednesday, 12 Jul 2017 08:40am EDT 

July 12 (Reuters) - Kindred Biosciences Inc :KindredBio announces pricing of public offering.Says public offering of 3.00 million common shares priced at $7.50 per share.  Full Article